Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals

Haydar Kuekrek, Tobias Schlingmann, Hernan Valdez, Bernhard O. Boehm, Richard B Pollard, Ronald Mitsuyasu, Frank Detlef Goebel, Michael M. Lederman, Paul V. Lehmann, Magdalena Tary-Lehmann

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Objectives: As interleukin (IL)-2 therapy increases CD4 cell counts in HIV infected subjects, it emerged as a candidate for the partial restoration of immune competence in this disease. Methods: We studied the frequencies of antigen-specific T cells using single cell resolution cytokine ELISPOT assays and titers of specific antibodies before and after immunization of HIV infected subjects who were treated with HAART or HAART plus IL-2. Results: Subjects seronegative to hepatitis A were vaccinated with hepatitis A antigen. In the non-IL-2 treated group, hepatitis A-specific T cells producing IL-2 and IL-4 along with specific antibodies were induced, showing that these subjects are immune competent and capable of mounting a primary immune response. Additional IL-2 treatment had no significant effect on this primary T cell response; however, booster immunizations with tetanus toxoid or the gp120 depleted HIV vaccine Remune induced higher frequencies of specific interferon (IFN)-γ producing T cells in IL-2 treated subjects. No impact of IL-2 treatment on these secondary B cell responses was seen. Conclusion: Overall, our study showed that IL-2 therapy had no immune enhancing effect on the induction of a primary response, but increased the frequency of IFN-γ producing memory cells after booster immunization.

Original languageEnglish (US)
Pages (from-to)1967-1974
Number of pages8
JournalAIDS
Volume19
Issue number17
StatePublished - Nov 2005

Fingerprint

Secondary Immunization
Interleukin-2
HIV
T-Lymphocytes
Hepatitis A
Highly Active Antiretroviral Therapy
Interferons
Therapeutics
Hepatitis A Antigens
HIV Envelope Protein gp120
Enzyme-Linked Immunospot Assay
AIDS Vaccines
Tetanus Toxoid
Antibodies
CD4 Lymphocyte Count
Interleukin-4
Mental Competency
Immunization
B-Lymphocytes
Cytokines

Keywords

  • AIDS vaccine
  • B cells
  • Cytokines
  • ELISPOT
  • HIV
  • Th1 response
  • Th2 response

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Kuekrek, H., Schlingmann, T., Valdez, H., Boehm, B. O., Pollard, R. B., Mitsuyasu, R., ... Tary-Lehmann, M. (2005). Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. AIDS, 19(17), 1967-1974.

Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. / Kuekrek, Haydar; Schlingmann, Tobias; Valdez, Hernan; Boehm, Bernhard O.; Pollard, Richard B; Mitsuyasu, Ronald; Goebel, Frank Detlef; Lederman, Michael M.; Lehmann, Paul V.; Tary-Lehmann, Magdalena.

In: AIDS, Vol. 19, No. 17, 11.2005, p. 1967-1974.

Research output: Contribution to journalArticle

Kuekrek, H, Schlingmann, T, Valdez, H, Boehm, BO, Pollard, RB, Mitsuyasu, R, Goebel, FD, Lederman, MM, Lehmann, PV & Tary-Lehmann, M 2005, 'Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals', AIDS, vol. 19, no. 17, pp. 1967-1974.
Kuekrek H, Schlingmann T, Valdez H, Boehm BO, Pollard RB, Mitsuyasu R et al. Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. AIDS. 2005 Nov;19(17):1967-1974.
Kuekrek, Haydar ; Schlingmann, Tobias ; Valdez, Hernan ; Boehm, Bernhard O. ; Pollard, Richard B ; Mitsuyasu, Ronald ; Goebel, Frank Detlef ; Lederman, Michael M. ; Lehmann, Paul V. ; Tary-Lehmann, Magdalena. / Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals. In: AIDS. 2005 ; Vol. 19, No. 17. pp. 1967-1974.
@article{955a3a980286484ba238bb9a92232b64,
title = "Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals",
abstract = "Objectives: As interleukin (IL)-2 therapy increases CD4 cell counts in HIV infected subjects, it emerged as a candidate for the partial restoration of immune competence in this disease. Methods: We studied the frequencies of antigen-specific T cells using single cell resolution cytokine ELISPOT assays and titers of specific antibodies before and after immunization of HIV infected subjects who were treated with HAART or HAART plus IL-2. Results: Subjects seronegative to hepatitis A were vaccinated with hepatitis A antigen. In the non-IL-2 treated group, hepatitis A-specific T cells producing IL-2 and IL-4 along with specific antibodies were induced, showing that these subjects are immune competent and capable of mounting a primary immune response. Additional IL-2 treatment had no significant effect on this primary T cell response; however, booster immunizations with tetanus toxoid or the gp120 depleted HIV vaccine Remune induced higher frequencies of specific interferon (IFN)-γ producing T cells in IL-2 treated subjects. No impact of IL-2 treatment on these secondary B cell responses was seen. Conclusion: Overall, our study showed that IL-2 therapy had no immune enhancing effect on the induction of a primary response, but increased the frequency of IFN-γ producing memory cells after booster immunization.",
keywords = "AIDS vaccine, B cells, Cytokines, ELISPOT, HIV, Th1 response, Th2 response",
author = "Haydar Kuekrek and Tobias Schlingmann and Hernan Valdez and Boehm, {Bernhard O.} and Pollard, {Richard B} and Ronald Mitsuyasu and Goebel, {Frank Detlef} and Lederman, {Michael M.} and Lehmann, {Paul V.} and Magdalena Tary-Lehmann",
year = "2005",
month = "11",
language = "English (US)",
volume = "19",
pages = "1967--1974",
journal = "AIDS",
issn = "0269-9370",
publisher = "Lippincott Williams and Wilkins",
number = "17",

}

TY - JOUR

T1 - Differential effect of interleukin-2 treatment on primary and secondary immunizations in HIV infected individuals

AU - Kuekrek, Haydar

AU - Schlingmann, Tobias

AU - Valdez, Hernan

AU - Boehm, Bernhard O.

AU - Pollard, Richard B

AU - Mitsuyasu, Ronald

AU - Goebel, Frank Detlef

AU - Lederman, Michael M.

AU - Lehmann, Paul V.

AU - Tary-Lehmann, Magdalena

PY - 2005/11

Y1 - 2005/11

N2 - Objectives: As interleukin (IL)-2 therapy increases CD4 cell counts in HIV infected subjects, it emerged as a candidate for the partial restoration of immune competence in this disease. Methods: We studied the frequencies of antigen-specific T cells using single cell resolution cytokine ELISPOT assays and titers of specific antibodies before and after immunization of HIV infected subjects who were treated with HAART or HAART plus IL-2. Results: Subjects seronegative to hepatitis A were vaccinated with hepatitis A antigen. In the non-IL-2 treated group, hepatitis A-specific T cells producing IL-2 and IL-4 along with specific antibodies were induced, showing that these subjects are immune competent and capable of mounting a primary immune response. Additional IL-2 treatment had no significant effect on this primary T cell response; however, booster immunizations with tetanus toxoid or the gp120 depleted HIV vaccine Remune induced higher frequencies of specific interferon (IFN)-γ producing T cells in IL-2 treated subjects. No impact of IL-2 treatment on these secondary B cell responses was seen. Conclusion: Overall, our study showed that IL-2 therapy had no immune enhancing effect on the induction of a primary response, but increased the frequency of IFN-γ producing memory cells after booster immunization.

AB - Objectives: As interleukin (IL)-2 therapy increases CD4 cell counts in HIV infected subjects, it emerged as a candidate for the partial restoration of immune competence in this disease. Methods: We studied the frequencies of antigen-specific T cells using single cell resolution cytokine ELISPOT assays and titers of specific antibodies before and after immunization of HIV infected subjects who were treated with HAART or HAART plus IL-2. Results: Subjects seronegative to hepatitis A were vaccinated with hepatitis A antigen. In the non-IL-2 treated group, hepatitis A-specific T cells producing IL-2 and IL-4 along with specific antibodies were induced, showing that these subjects are immune competent and capable of mounting a primary immune response. Additional IL-2 treatment had no significant effect on this primary T cell response; however, booster immunizations with tetanus toxoid or the gp120 depleted HIV vaccine Remune induced higher frequencies of specific interferon (IFN)-γ producing T cells in IL-2 treated subjects. No impact of IL-2 treatment on these secondary B cell responses was seen. Conclusion: Overall, our study showed that IL-2 therapy had no immune enhancing effect on the induction of a primary response, but increased the frequency of IFN-γ producing memory cells after booster immunization.

KW - AIDS vaccine

KW - B cells

KW - Cytokines

KW - ELISPOT

KW - HIV

KW - Th1 response

KW - Th2 response

UR - http://www.scopus.com/inward/record.url?scp=27944487962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27944487962&partnerID=8YFLogxK

M3 - Article

C2 - 16260902

AN - SCOPUS:27944487962

VL - 19

SP - 1967

EP - 1974

JO - AIDS

JF - AIDS

SN - 0269-9370

IS - 17

ER -